Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in two upcoming investor conferences. On August 13, 2024, at 3:00 pm Eastern Time, CEO Brian Strem will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. Additionally, on August 15, 2024, Strem will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Both presentations will be available via live webcast, with registration links provided. Replays of the presentations will be accessible on-demand for 90 days on Kiora's investor relations homepage (ir.kiorapharma.com). These conferences offer investors an opportunity to gain insights into Kiora's latest developments and future prospects.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha annunciato la sua partecipazione a due conferenze per investitori imminenti. Il 13 agosto 2024, alle ore 15:00 Eastern Time, il CEO Brian Strem presenterà alla 44esima Conferenza Annuale sulla Crescita di Canaccord Genuity e Vetrina per le Aziende Private. Inoltre, il 15 agosto 2024, Strem presenterà alla 4a Conferenza Virtuale Annuale di Oftalmologia di H.C. Wainwright.
Entrambe le presentazioni saranno disponibili tramite webcast dal vivo, con i link per la registrazione forniti. Le registrazioni delle presentazioni saranno accessibili on-demand per 90 giorni sulla homepage delle relazioni con gli investitori di Kiora (ir.kiorapharma.com). Queste conferenze offrono agli investitori l'opportunità di acquisire informazioni sugli sviluppi più recenti di Kiora e sulle prospettive future.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha anunciado su participación en dos futuras conferencias para inversores. El 13 de agosto de 2024, a las 3:00 p.m. hora del Este, el CEO Brian Strem presentará en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity y Vitrina de Empresas Privadas. Además, el 15 de agosto de 2024, Strem presentará en la 4ª Conferencia Virtual Anual de Oftalmología de H.C. Wainwright.
Ambas presentaciones estarán disponibles a través de webcast en vivo, con enlaces de registro proporcionados. Las repeticiones de las presentaciones estarán accesibles on-demand durante 90 días en la página de relaciones con inversores de Kiora (ir.kiorapharma.com). Estas conferencias ofrecen a los inversores la oportunidad de conocer los últimos desarrollos y las perspectivas futuras de Kiora.
키오라 제약 (NASDAQ: KPRX)는 다가오는 투자자 회의에 참여할 예정이라고 발표했습니다. 2024년 8월 13일 오후 3시 (동부 표준시)에 CEO 브라이언 스트렘이 캐너지 제뉴이티 제44회 연례 성장 회의 및 민간 기업 쇼케이스에서 발표할 예정입니다. 또한, 2024년 8월 15일에는 스트렘이 H.C. 웨인라이트 제4회 연례 안과 가상 회의에서 발표합니다.
두 발표 모두 실시간 웹캐스트를 통해 제공되며, 등록 링크가 제공됩니다. 발표 재생은 키오라의 투자자 관계 홈페이지(ir.kiorapharma.com)에서 90일 간 온디맨드로 접근할 수 있습니다. 이러한 회의는 투자자들에게 키오라의 최신 개발 및 향후 전망에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Kiora Pharmaceuticals (NASDAQ: KPRX) a annoncé sa participation à deux prochaines conférences pour investisseurs. Le 13 août 2024 à 15h00, heure de l'Est, le PDG Brian Strem présentera lors de la 44ème conférence annuelle sur la croissance de Canaccord Genuity et vitrine des entreprises privées. De plus, le 15 août 2024, Strem présentera à la 4ème conférence virtuelle annuelle sur l'ophtalmologie de H.C. Wainwright.
Les deux présentations seront disponibles via webcast en direct, avec des liens d'inscription fournis. Les rediffusions des présentations seront accessibles à la demande pendant 90 jours sur la page des relations investisseurs de Kiora (ir.kiorapharma.com). Ces conférences offrent aux investisseurs une occasion d'obtenir des informations sur les derniers développements et les perspectives futures de Kiora.
Kiora Pharmaceuticals (NASDAQ: KPRX) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Am 13. August 2024 um 15:00 Uhr Eastern Time wird CEO Brian Strem auf der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity & Privatunternehmen Vitrine präsentieren. Darüber hinaus wird Strem am 15. August 2024 auf der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright präsentieren.
Beide Präsentationen werden über Live-Webcast verfügbar sein, mit bereitgestellten Registrierungslinks. Die Wiederholungen der Präsentationen werden 90 Tage on-Demand auf der Investor-Relations-Homepage von Kiora (ir.kiorapharma.com) zugänglich sein. Diese Konferenzen bieten Investoren die Möglichkeit, Einblicke in die neuesten Entwicklungen und zukünftigen Perspektiven von Kiora zu erhalten.
- None.
- None.
Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast.
On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D., will participate at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The presentation will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com).
On Thursday August 15th, 2024, Kiora's President and CEO, Brian Strem, Ph.D., will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The webcast will be available live from this registration link and the replay will be available on-demand for 90 days on our IR homepage (ir.kiorapharma.com).
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218902
FAQ
When is Kiora Pharmaceuticals (KPRX) presenting at the Canaccord Genuity Conference?
Which conferences will Kiora Pharmaceuticals (KPRX) participate in during August 2024?
How can investors access Kiora Pharmaceuticals' (KPRX) conference presentations?
Who will be presenting on behalf of Kiora Pharmaceuticals (KPRX) at the upcoming conferences?
